
Lexeo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

I'm PortAI, I can summarize articles.
Lexeo Therapeutics Inc reported a quarterly adjusted loss of 99 cents per share for the quarter ended March 31, compared to a loss of 77 cents in the same quarter last year. The reported revenue was zero, matching analyst expectations. The company incurred a quarterly loss of $32.66 million, with shares falling 22.5% this quarter and 59.1% year-to-date. Analysts maintain a "buy" rating, with a median 12-month price target of $21.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

